Noradrenergic drugs may improve Alzheimer’s symptoms, review finds
Studies suggest the agents may improve cognition and apathy but not memory
Commonly prescribed noradrenergic drugs such as methylphenidate could be repurposed to treat general cognitive symptoms and apathy in Alzheimer’s disease, neurology researchers suggest.
Results from a systematic review and meta-analysis of 19 clinical trials suggest that targeting noradrenergic dysfunction in affected patients could also have disease-modifying effects, they said.
